Notice names this product. SUN PHARMACEUTICAL INDUSTRIES’s DOXOrubin Hydrochloride Liposome injection is named in FDA Class I recall D-0580-2026. Your particular item is not yet verified. Compare the identifiers and exclusions in the notice before deciding whether it applies. Agency-reported hazard: Presence of Particulate matter: Particulate matter identified as glass. Identifying details: Lot HAG2581B, expires: 05/31/2027. Units affected: 675 vials. Status: Ongoing.
This notice names a product; your particular item is not yet verified. Compare every applicable model, serial, lot, production-date or model-year boundary below.
DOXOrubin Hydrochloride Liposome injection, 50 mg/25 mL (2mg/mL), 25 mL single-dose vials, Sterile, Rx only, Manufactured for: Northstar Rx LLC., Memphis, TN 38141, Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol, Gujarat, India, NDC 72603-200-01.
Still to verify: match the label on your item with the full official notice, including any exclusions, tables and photos. Some identifiers appear only on the agency website and are absent from this data feed. A missing field does not mean all versions are affected.
If your lot or date falls outside a stated range, this notice has not established that your item is affected. This is not a finding about other recalls or product safety.
Presence of Particulate matter: Particulate matter identified as glass.
Company / brand: SUN PHARMACEUTICAL INDUSTRIES
Affected product: DOXOrubin Hydrochloride Liposome injection
Official ID D-0580-2026 · Official record ↗
See all SUN PHARMACEUTICAL INDUSTRIES recalls →
Found something wrong or missing? Report a data error.
Compiled from connected official public-domain government data. Sources last checked September 7, 2026 at 6:00 AM UTC.